AR051333A1 - Derivados de benzodiaepina sustituida por halogeno - Google Patents

Derivados de benzodiaepina sustituida por halogeno

Info

Publication number
AR051333A1
AR051333A1 ARP050104347A ARP050104347A AR051333A1 AR 051333 A1 AR051333 A1 AR 051333A1 AR P050104347 A ARP050104347 A AR P050104347A AR P050104347 A ARP050104347 A AR P050104347A AR 051333 A1 AR051333 A1 AR 051333A1
Authority
AR
Argentina
Prior art keywords
halogen
lower alkyl
substituted
hydrogen
cycloalkyl
Prior art date
Application number
ARP050104347A
Other languages
English (en)
Inventor
Henner Knust
Andrew William Thomas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35735152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR051333(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR051333A1 publication Critical patent/AR051333A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente se refiere a derivados de imidazo[1,5-a]-[1,2,4]triazolo[1,5-d][1,4]benzodiazepina sustituida por halogeno de la formula (1), en la que: R1 es hidrogeno, halogeno, alquilo inferior, Si(CH3) o alquilo inferior sustituido por halogeno o es alcoxi inferior o alcoxi inferior sustituido por halogeno o es alquenilo inferior, alqueniloxi inferior, CN, biciclo-[2.2.1.]hept-5-en-2-ilo, arilo opcionalmente sustituido por alquilo inferior, amino o alcoxi inferior o es ariloxi, heteroarilo, benzo[1,3]dioxolilo, cicloalquilo, heterocicloalquilo, -O(CH2)mOH, -C(O)O-alquilo inferior, -NR'2 o -C:::C-R''; R' es hidrogeno, alquilo inferior, cicloalquilo, -C(O)-alquilo inferior, -C(O)-cicloalquilo, -S(O)2-alquilo inferior o arilo, sin sustituir o sustituido por uno o dos sustituyentes elegidos entre el grupo formado por halogeno y alquilo inferior sustituido por halogeno; R'' es hidrogeno, -Si(CH3)3, alquilo inferior, cicloalquilo o -(CH2)m-O-alquilo inferior; R2 es hidrogeno, metilo o arilo; R3 es halogeno; R4 es hidrogeno o halogeno; n es 1 o 2; m es 1, 2 o 3; y a sus sales de adicion de ácido farmacéuticamente aceptables. Los compuestos pueden utilizarse para el tratamiento de la ampliacion cognitiva, trastornos cognitivos, ansiedad, enfermedad de Alzheimer y esquizofrenia.
ARP050104347A 2004-10-20 2005-10-18 Derivados de benzodiaepina sustituida por halogeno AR051333A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04105167 2004-10-20

Publications (1)

Publication Number Publication Date
AR051333A1 true AR051333A1 (es) 2007-01-03

Family

ID=35735152

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104347A AR051333A1 (es) 2004-10-20 2005-10-18 Derivados de benzodiaepina sustituida por halogeno

Country Status (17)

Country Link
US (1) US7507728B2 (es)
EP (1) EP1807432A1 (es)
JP (1) JP4751398B2 (es)
KR (1) KR100915469B1 (es)
CN (1) CN101084220B (es)
AR (1) AR051333A1 (es)
AU (1) AU2005299031B2 (es)
BR (1) BRPI0516244A (es)
CA (1) CA2584757C (es)
IL (1) IL182697A (es)
MX (1) MX2007004640A (es)
NO (1) NO20072046L (es)
NZ (1) NZ554556A (es)
RU (1) RU2007114763A (es)
TW (1) TWI304404B (es)
WO (1) WO2006045429A1 (es)
ZA (1) ZA200703244B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4885967B2 (ja) * 2005-10-11 2012-02-29 エフ．ホフマン−ラ ロシュ アーゲー イミダゾベンゾジアゼピン誘導体
EP2457569A1 (en) 2010-11-05 2012-05-30 F. Hoffmann-La Roche AG Use of active pharmaceutical compounds for the treatment of central nervous system conditions
AU2011325190B2 (en) 2010-11-05 2015-05-14 F. Hoffmann-La Roche Ag Use of active pharmaceutical compounds for the treatment of central nervous system conditions
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
AU2014368961B2 (en) * 2013-12-20 2019-10-17 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2016279052A1 (en) * 2015-06-19 2018-02-15 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) * 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2018330578B2 (en) * 2017-09-07 2022-11-10 Eisai R&D Management Co., Ltd. Pentacyclic compound
EA202190076A1 (ru) 2018-06-19 2021-09-22 Эйджинбайо, Инк. Производные бензодиазепина, композиции и способы лечения когнитивных нарушений
KR20210135223A (ko) 2019-03-05 2021-11-12 에자이 알앤드디 매니지먼트 가부시키가이샤 펜타시클릭 화합물의 염 및 이의 결정
AR118235A1 (es) 2019-03-05 2021-09-22 Eisai R&D Man Co Ltd Heterociclos pentacíclicos

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ180218A (en) * 1975-08-07 1983-07-15 Hoffmann La Roche 6-(phenyl or pyridyl)-4h-imidazo(1,5-a) (1,4) diazepines
CA1143728A (en) 1979-10-04 1983-03-29 Max Gerecke Imidazodiazepine derivatives
CA1174673A (en) * 1981-02-27 1984-09-18 Walter Hunkeler Imidazodiazepines
DE3587913D1 (de) 1984-01-19 1994-10-06 Hoffmann La Roche Imidazodiazepin-Derivate.
DK174086D0 (da) 1986-04-16 1986-04-16 Ferrosan As Nye benzodiazepinderivater samt fremgangsmaade til fremstilling af samme
US4897392A (en) 1989-07-03 1990-01-30 Hoechst-Roussel Pharmaceuticals, Inc. 4H-indolo(1,2-d)(1,2,4)triazolo(4,3-A)(1,4)benzodiazepines
TW201311B (es) * 1991-06-17 1993-03-01 Hoffmann La Roche
JPH078869A (ja) * 1993-06-29 1995-01-13 Mitsubishi Chem Corp 粉粒体のコーティング方法
TWI239333B (en) * 2000-11-16 2005-09-11 Hoffmann La Roche Benzodiazepine derivatives as GABA A receptor modulators
US6686352B2 (en) * 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives

Also Published As

Publication number Publication date
IL182697A (en) 2012-02-29
IL182697A0 (en) 2007-09-20
ZA200703244B (en) 2008-08-27
RU2007114763A (ru) 2008-11-27
AU2005299031A1 (en) 2006-05-04
WO2006045429A1 (en) 2006-05-04
JP2008517010A (ja) 2008-05-22
AU2005299031B2 (en) 2011-11-10
MX2007004640A (es) 2007-06-08
CA2584757A1 (en) 2006-05-04
BRPI0516244A (pt) 2008-08-26
US7507728B2 (en) 2009-03-24
JP4751398B2 (ja) 2011-08-17
CN101084220A (zh) 2007-12-05
TWI304404B (en) 2008-12-21
CN101084220B (zh) 2010-12-15
US20060084801A1 (en) 2006-04-20
NZ554556A (en) 2009-11-27
TW200630371A (en) 2006-09-01
EP1807432A1 (en) 2007-07-18
KR20070085398A (ko) 2007-08-27
CA2584757C (en) 2012-07-03
NO20072046L (no) 2007-04-26
KR100915469B1 (ko) 2009-09-03

Similar Documents

Publication Publication Date Title
AR051333A1 (es) Derivados de benzodiaepina sustituida por halogeno
AR046186A1 (es) Compuestos derivados de 1,3,8-triaza-espiro[4.5]decan-4-ona
AR059076A1 (es) Tiofenil y pirrolil azepinas como ligandos del receptor 5-ht2c de serotonina y usos de las mismas
AR051395A1 (es) Derivados de imidazo- benzodiazepina, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos, y usos en terapeutica
PE20180500A1 (es) Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores del receptor muscarinico colinergico m1
AR074966A1 (es) Compuestos amino-heterociclicos
AR064299A1 (es) Derivados de sulfonil-fenil-2h- [1,2,4] oxadiazol-5-ona procesos para su preparacion y su uso como agentes farmaceuticos
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
ECSP099728A (es) Compuestos amino-heterocíclicos
AR038341A1 (es) Compuestos que son agonistas de receptores alfa-1 preferentemente agonistas de receptores alfa-1a/l
HRP20100076T1 (hr) Heterociklički supstituirani fenil metanoni kao inhibitori glicin transportera 1
PE20071325A1 (es) Derivados de n-heteroaril-carboxamidas triciclicas que contienen un resto bencimidazol, su preparacion y su aplicacion en terapeutica
MX2007004250A (es) Derivados de imidazo[1,5-a]triazolo[1,5-d]benzodiazepina para el tratamiento de trastornos cognitivos.
PE20091621A1 (es) Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen
AR056879A1 (es) Antagonistas del receptor 3 de la histamina
CO6260069A2 (es) Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno a4 hidrolasa
AR071778A1 (es) Imidazo[1,2-b]piridazinas inhibidores de proteinquinasas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento del cancer, enfermedades oseas y autoinmunes, entre otras.
AR067845A1 (es) Compuestos para tratar trastornos relacionados con la modulacion de receptores de rianodina y composicion farmaceutica
AR055005A1 (es) Imidazo-benzodiazepinas tetraciclicas, procedimiento de obtencion de los mismos medicamentos y su uso de los compuestos para su fabricacion
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
AR074358A1 (es) Derivados de pirazina como inhibidores de la fosfodiesterasa 10
PE20061156A1 (es) Derivados de benzamida como agentes inhibidores del transportador de glicina
AR071925A1 (es) Malonamidas como antagonistas de orexina
AR074226A1 (es) Octahidrociclopenta[c]pirrol-4-aminas sustituidas como bloqueantes de los canales de calcio, composiciones farmaceuticas que las comprenden y el uso de las mismas para el tratamiento del dolor.

Legal Events

Date Code Title Description
FB Suspension of granting procedure